No peptide has been shown to extend human lifespan. What exists is a spectrum of evidence. At the top, SS-31 (elamipretide) became the first mitochondria-targeted peptide approved by the FDA in 2025, for a rare mitochondrial disease, not for aging. NAD+ precursors have small human trials with mixed results. MOTS-c has impressive mouse data on metabolism and physical decline. GHK-Cu has human skin data. Epitalon has a striking telomerase story built mostly on one research group’s work.
For perspective: the interventions with the strongest longevity-related evidence today are exercise, not smoking, and, among drugs, things like rapamycin in mice and GLP-1 drugs for cardiovascular events in people. Here is the full ranking.
How longevity is measured (and why it’s hard)
Testing whether something makes humans live longer would take decades and tens of thousands of people. So longevity research leans on shortcuts, each with limits:
- Lifespan in short-lived animals (worms, flies, mice). Many results do not translate to people.
- Healthspan: measures of function such as muscle strength, endurance and metabolic health in older animals or humans.
- Biomarkers: telomere length, epigenetic clocks, NAD+ levels, inflammation markers. Useful, but changing a biomarker is not the same as living longer.
- The hallmarks of aging: a framework listing processes like mitochondrial dysfunction, cellular senescence, telomere attrition and loss of protein maintenance (López-Otín et al., 2013). Most longevity peptides target one hallmark.
The ranking at a glance
| Peptide | Hallmark targeted | Best evidence | Human data | From |
|---|---|---|---|---|
| SS-31 | Mitochondrial dysfunction | FDA approval (Barth syndrome) | Yes, disease trials | $69 |
| NAD+ | Metabolic / mitochondrial | Small human trials of precursors | Some, mixed | $26 |
| MOTS-c | Metabolic, physical decline | Mouse lifespan-adjacent data | Minimal | $55 |
| GHK-Cu | Tissue repair, gene expression | Skin studies | Topical only | $49 |
| Epitalon | Telomere attrition | Cell culture, Russian studies | Limited, unreplicated | $26 |
| Pinealon | Neuroprotection | Animal and cell studies | Minimal | $44 |
1. SS-31 (elamipretide): the most validated
SS-31 is a four-amino-acid peptide that concentrates in the inner membrane of mitochondria, where it binds cardiolipin, a fat that holds the energy-producing machinery together. By stabilizing cardiolipin, it is thought to improve energy production and reduce oxidative damage.
It is the only peptide on this list with a regulatory approval: in September 2025 the FDA granted accelerated approval to elamipretide for Barth syndrome, a rare inherited mitochondrial disease. That is a big milestone for the mitochondrial-peptide field. It is not evidence that SS-31 slows normal aging: trials in other conditions, including age-related ones, have been mixed. More in our SS-31 guide and MOTS-c vs SS-31.
2. NAD+: the most studied in humans
NAD+ is a coenzyme every cell needs to make energy and repair DNA, and its levels decline with age in many tissues. Raising it has become a central longevity strategy, mostly through oral precursors:
- In a 10-week trial, NMN improved muscle insulin sensitivity in overweight prediabetic women (Yoshino et al., 2021).
- Trials of NR raised blood NAD+ levels reliably but showed modest or no changes in many functional outcomes.
So precursors raise NAD+, and the downstream benefits in humans are real in some measures and absent in others. Direct NAD+ injections and IV drips are popular at clinics but have much less trial data than oral precursors. See our NAD+ research guide and NAD+ injection side effects.
3. MOTS-c: the exercise-mimetic peptide
MOTS-c is unusual: it is encoded by mitochondrial DNA, not the nucleus. Discovered in 2015, it improved insulin sensitivity and prevented diet-induced obesity in mice (Lee et al., 2015). Later work found MOTS-c levels rise with exercise, and that treating older mice improved physical capacity and muscle function, earning it the nickname “exercise mimetic” (Reynolds et al., 2021).
Promising, and still almost entirely preclinical. See MOTS-c side effects.
4. GHK-Cu: the gene-expression peptide
GHK-Cu is a copper-binding tripeptide whose levels in plasma fall with age. Analyses of gene-expression databases suggest it nudges thousands of genes toward patterns associated with tissue repair and away from patterns linked to inflammation and degradation (Pickart & Margolina, 2018). The best human evidence is in skin, where it is a well-tolerated cosmetic ingredient. Whole-body longevity effects are untested. See retinol vs vitamin C vs copper peptides.
5. Epitalon and Pinealon: the bioregulators
Epitalon (also Epithalon) is a four-amino-acid peptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson in Russia, modelled on an extract of the pineal gland. Its fame comes from a 2003 study in which it activated telomerase and elongated telomeres in human cells in culture (Khavinson et al., 2003). Russian studies in animals and elderly people have reported extended lifespan and improved biomarkers.
The caveat is significant: most of this research comes from one group, many studies are in Russian journals that are hard to evaluate, and independent Western replication is lacking. Telomerase activation also carries a theoretical concern, since many cancers rely on telomerase. Pinealon, a three-amino-acid peptide from the same school, is studied for neuroprotection. See Epitalon side effects.
What beats all of them
For honest context, here is where the strongest longevity-related evidence actually sits:
| Intervention | Evidence |
|---|---|
| Exercise, especially cardiorespiratory fitness and strength | Among the strongest predictors of longer life in large human studies |
| Not smoking, sleep, healthy weight | Very strong human evidence |
| Rapamycin | Extended lifespan in mice, even started late in life (Harrison et al., 2009); human data emerging |
| GLP-1 drugs (semaglutide) | Reduced major cardiovascular events by 20% in people with obesity and heart disease (Lincoff et al., 2023) |
Peptides are interesting research tools on specific hallmarks of aging. They are not a substitute for the basics.
How to read longevity claims
- Was it in humans? Mouse lifespan studies are a starting point, not an answer.
- Was it replicated by an independent group?
- Did it change outcomes, or just a biomarker? Longer telomeres or higher NAD+ are not the same as longer life.
- Who funded it? Industry studies are not automatically wrong, but they deserve extra scrutiny.
- Is the product what it claims? For research compounds, demand a batch-specific certificate of analysis.
FAQ
Tap a question to reveal the answer.
What is the best peptide for longevity?
None has been shown to extend human lifespan. SS-31 has the strongest clinical validation (FDA approval for Barth syndrome), NAD+ precursors have the most human trials, and MOTS-c has notable mouse data on physical decline.
Does Epitalon really lengthen telomeres?
In a 2003 cell-culture study it activated telomerase and lengthened telomeres in human cells. Evidence in living people comes mainly from one Russian research group and has not been independently replicated.
Is SS-31 approved?
Elamipretide (SS-31) received FDA accelerated approval in September 2025 for Barth syndrome, a rare mitochondrial disease. It is not approved for aging, and not approved in Canada.
Does NAD+ reverse aging?
NAD+ precursors reliably raise NAD+ levels and improved some metabolic measures in small human trials, but they have not been shown to reverse aging.
What is MOTS-c?
A peptide encoded by mitochondrial DNA, discovered in 2015, that improved metabolism and physical capacity in mice. It is sometimes called an exercise mimetic. Human data are minimal.
Related reading
References
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–1217. PubMed
- US FDA. FDA grants accelerated approval for first treatment for Barth syndrome. September 19, 2025. FDA
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229. PubMed
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. PubMed
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470. PubMed
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PubMed
- Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590–592. PubMed
- Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392–395. PubMed
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221–2232. PubMed
This article is general information, not medical advice. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.